vs

Side-by-side financial comparison of INNODATA INC (INOD) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $72.4M, roughly 1.1× INNODATA INC). INNODATA INC runs the higher net margin — 12.2% vs -38.1%, a 50.3% gap on every dollar of revenue. On growth, INNODATA INC posted the faster year-over-year revenue change (22.3% vs 20.2%). Over the past eight quarters, INNODATA INC's revenue compounded faster (65.3% CAGR vs 24.8%).

Innodata Inc., formerly Innodata Isogen, Inc., is an American company that provides business process, technology and consulting services. The company also provides products that aim to help clients create, manage, use and distribute digital information.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

INOD vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.1× larger
PRCT
$83.1M
$72.4M
INOD
Growing faster (revenue YoY)
INOD
INOD
+2.1% gap
INOD
22.3%
20.2%
PRCT
Higher net margin
INOD
INOD
50.3% more per $
INOD
12.2%
-38.1%
PRCT
Faster 2-yr revenue CAGR
INOD
INOD
Annualised
INOD
65.3%
24.8%
PRCT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
INOD
INOD
PRCT
PRCT
Revenue
$72.4M
$83.1M
Net Profit
$8.8M
$-31.6M
Gross Margin
38.3%
64.9%
Operating Margin
15.1%
-4.1%
Net Margin
12.2%
-38.1%
Revenue YoY
22.3%
20.2%
Net Profit YoY
-14.2%
-27.9%
EPS (diluted)
$0.26
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INOD
INOD
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$72.4M
$76.4M
Q3 25
$62.5M
$83.3M
Q2 25
$58.4M
$79.2M
Q1 25
$58.3M
$69.2M
Q4 24
$59.2M
$68.2M
Q3 24
$52.2M
$58.4M
Q2 24
$32.6M
$53.4M
Net Profit
INOD
INOD
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$8.8M
$-29.8M
Q3 25
$8.3M
$-21.4M
Q2 25
$7.2M
$-19.6M
Q1 25
$7.8M
$-24.7M
Q4 24
$10.3M
$-18.9M
Q3 24
$17.4M
$-21.0M
Q2 24
$-14.0K
$-25.6M
Gross Margin
INOD
INOD
PRCT
PRCT
Q1 26
64.9%
Q4 25
38.3%
60.6%
Q3 25
40.8%
64.8%
Q2 25
39.4%
65.4%
Q1 25
39.9%
63.9%
Q4 24
45.2%
64.0%
Q3 24
40.8%
63.2%
Q2 24
28.7%
59.0%
Operating Margin
INOD
INOD
PRCT
PRCT
Q1 26
-4.1%
Q4 25
15.1%
-40.6%
Q3 25
18.8%
-27.8%
Q2 25
15.3%
-28.0%
Q1 25
14.2%
-39.7%
Q4 24
19.0%
-28.9%
Q3 24
21.9%
-38.4%
Q2 24
1.0%
-50.3%
Net Margin
INOD
INOD
PRCT
PRCT
Q1 26
-38.1%
Q4 25
12.2%
-39.1%
Q3 25
13.3%
-25.7%
Q2 25
12.4%
-24.7%
Q1 25
13.3%
-35.8%
Q4 24
17.4%
-27.6%
Q3 24
33.3%
-35.9%
Q2 24
-0.0%
-48.0%
EPS (diluted)
INOD
INOD
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.26
$-0.54
Q3 25
$0.24
$-0.38
Q2 25
$0.20
$-0.35
Q1 25
$0.22
$-0.45
Q4 24
$0.35
$-0.34
Q3 24
$0.51
$-0.40
Q2 24
$0.00
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INOD
INOD
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$82.2M
$245.6M
Total DebtLower is stronger
$51.7M
Stockholders' EquityBook value
$107.1M
$347.7M
Total Assets
$168.6M
$487.1M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INOD
INOD
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$82.2M
$286.5M
Q3 25
$73.9M
$294.3M
Q2 25
$59.8M
$302.7M
Q1 25
$56.6M
$316.2M
Q4 24
$46.9M
$333.7M
Q3 24
$26.4M
$196.8M
Q2 24
$16.5M
$214.1M
Total Debt
INOD
INOD
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
INOD
INOD
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$107.1M
$365.9M
Q3 25
$97.3M
$380.3M
Q2 25
$86.7M
$385.8M
Q1 25
$75.5M
$389.2M
Q4 24
$63.5M
$402.2M
Q3 24
$47.7M
$241.2M
Q2 24
$29.0M
$251.8M
Total Assets
INOD
INOD
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$168.6M
$508.1M
Q3 25
$152.9M
$511.5M
Q2 25
$132.6M
$513.1M
Q1 25
$125.2M
$519.4M
Q4 24
$113.4M
$534.0M
Q3 24
$88.2M
$374.1M
Q2 24
$66.0M
$374.4M
Debt / Equity
INOD
INOD
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INOD
INOD
PRCT
PRCT
Operating Cash FlowLast quarter
$12.9M
Free Cash FlowOCF − Capex
$10.1M
FCF MarginFCF / Revenue
13.9%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
1.46×
TTM Free Cash FlowTrailing 4 quarters
$35.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INOD
INOD
PRCT
PRCT
Q1 26
Q4 25
$12.9M
$-10.3M
Q3 25
$18.8M
$-6.6M
Q2 25
$4.2M
$-15.0M
Q1 25
$10.9M
$-17.0M
Q4 24
$17.2M
$-32.4M
Q3 24
$11.4M
$-18.8M
Q2 24
$-454.0K
$-15.7M
Free Cash Flow
INOD
INOD
PRCT
PRCT
Q1 26
Q4 25
$10.1M
$-12.2M
Q3 25
$14.5M
$-9.5M
Q2 25
$2.5M
$-17.8M
Q1 25
$8.5M
$-18.8M
Q4 24
$15.0M
$-33.6M
Q3 24
$9.9M
$-19.0M
Q2 24
$-3.2M
$-16.8M
FCF Margin
INOD
INOD
PRCT
PRCT
Q1 26
Q4 25
13.9%
-15.9%
Q3 25
23.2%
-11.4%
Q2 25
4.3%
-22.5%
Q1 25
14.6%
-27.2%
Q4 24
25.3%
-49.2%
Q3 24
19.0%
-32.6%
Q2 24
-9.8%
-31.4%
Capex Intensity
INOD
INOD
PRCT
PRCT
Q1 26
Q4 25
3.9%
2.4%
Q3 25
6.8%
3.4%
Q2 25
2.9%
3.5%
Q1 25
4.0%
2.7%
Q4 24
3.7%
1.7%
Q3 24
2.8%
0.4%
Q2 24
8.4%
2.0%
Cash Conversion
INOD
INOD
PRCT
PRCT
Q1 26
Q4 25
1.46×
Q3 25
2.25×
Q2 25
0.59×
Q1 25
1.40×
Q4 24
1.67×
Q3 24
0.65×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INOD
INOD

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons